| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/18/2004 | CN1475206A Medical composition containing micropowdery bicyclic medicine |
| 02/18/2004 | CN1138779C Substituted triazolo-pyridazing derivative, pharmaceutical composition made therefrom |
| 02/18/2004 | CN1138775C Acetylcholine enhancers and its use |
| 02/18/2004 | CN1138774C Substituted 6,6-hetero-bicyclic derivatives |
| 02/18/2004 | CN1138771C 6-hydroxy-3-(4-[2-piperidine-1-group) oxyethyl group] phenoxy)-2-(4-methoxyphenyl) benzo[b] thiophene hydrochloride salt |
| 02/18/2004 | CN1138770C 6-carbonyl-3-(4-[2-pierid-1-yl)elhoyl]phenoxy)-2-(4-methoxylphenyl) benzo[b] thiophene salt crystal |
| 02/18/2004 | CN1138761C 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and use as dopamine autoreceptor (D2) agonists |
| 02/18/2004 | CN1138760C Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 02/18/2004 | CN1138755C Cyclic amino acids and derivs thereof useful as pharmaceutical agents |
| 02/18/2004 | CN1138753C Dimethyl-substituted cyclohexane diene derivatives |
| 02/18/2004 | CN1138591C Coated particles, method of making and using |
| 02/18/2004 | CN1138546C Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine |
| 02/18/2004 | CN1138545C Use of penciclovir for treatment of human herpes-virus-8 |
| 02/18/2004 | CN1138540C Antalgic and sedative oral etomidate preparation |
| 02/18/2004 | CN1138535C Pharmaceutical compositions contg. effervescent acid -base couple |
| 02/18/2004 | CN1138529C Fizzy formulation |
| 02/18/2004 | CN1138472C Dipeptide apoptosis inhibitors and use thereof |
| 02/17/2004 | US6693197 Process for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino- [2,3-f] quinoline |
| 02/17/2004 | US6693128 Substituted dicinnamoylquinides and their use in augmentation of adenonsine function |
| 02/17/2004 | US6693120 Spray drying of thrombin inhibitors |
| 02/17/2004 | US6693117 Compounds with analgesic effect |
| 02/17/2004 | US6693116 Adenosine receptor ligands |
| 02/17/2004 | US6693111 Indole-2,3-dione-3-oxime derivatives |
| 02/17/2004 | US6693108 Pyrimidinyl-guanidine derivatives |
| 02/17/2004 | US6693106 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's) |
| 02/17/2004 | US6693102 Pyridine-substituted pyrazolopyridine derivatives |
| 02/17/2004 | US6693098 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases |
| 02/17/2004 | US6693096 Treatment of inflammation-associated disorders using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| 02/17/2004 | US6693079 Insulin-like growth factor agonist molecules |
| 02/17/2004 | US6693078 Insulin-like growth factor agonist molecules |
| 02/17/2004 | US6692943 Persephin and related growth factors |
| 02/17/2004 | US6692744 Betaglycan as an inhibin receptor and uses thereof |
| 02/17/2004 | CA2290969C Delayed-release dosage forms of sertraline |
| 02/17/2004 | CA2252401C Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
| 02/17/2004 | CA2124680C Piperazine derivatives as 5-ht1a antagonists |
| 02/17/2004 | CA2079161C N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines |
| 02/14/2004 | CA2454644A1 Cannabinoid liquid formulations for mucosal administration |
| 02/12/2004 | WO2004013174A1 Use of disease-associated gene |
| 02/12/2004 | WO2004013146A1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| 02/12/2004 | WO2004013144A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/12/2004 | WO2004013143A2 Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands |
| 02/12/2004 | WO2004013140A1 Pyrazole compositions useful as inhibitors of gsk-3 |
| 02/12/2004 | WO2004013138A2 Imidazo`1,2-a!pyridines |
| 02/12/2004 | WO2004013137A1 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity |
| 02/12/2004 | WO2004013136A1 Benzothiophene urea, benzofurane urea, and indole urea, and use of the same as alpha-7 achr agonists |
| 02/12/2004 | WO2004013135A1 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| 02/12/2004 | WO2004013134A2 Compounds |
| 02/12/2004 | WO2004013130A1 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 02/12/2004 | WO2004013125A1 Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway |
| 02/12/2004 | WO2004013114A1 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| 02/12/2004 | WO2004013109A1 Resorcinol derivative |
| 02/12/2004 | WO2004013108A1 Method and compounds for promoting healing and reducing inflammation |
| 02/12/2004 | WO2004013107A1 Drugs for preventing and/or treating spinal injury |
| 02/12/2004 | WO2004013102A1 Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines |
| 02/12/2004 | WO2004013101A2 N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy |
| 02/12/2004 | WO2004013100A2 N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy |
| 02/12/2004 | WO2004013087A1 Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof |
| 02/12/2004 | WO2004013077A2 Cyclopentanone and cyclopentanone derivatives as potent activators of hsf-1 |
| 02/12/2004 | WO2004012768A1 Tolerance induction with help of a combination of a lfa-1 inhibitor and a costimulation inhibitor and/or a mtor inhibitor |
| 02/12/2004 | WO2004012761A1 Methods of use of compounds with preptin function |
| 02/12/2004 | WO2004012754A1 Composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs |
| 02/12/2004 | WO2004012753A1 Pharmaceutical composition containing black cumin oil, flax oil and borago oil |
| 02/12/2004 | WO2004012750A1 Method of preparing platelet rich plasma |
| 02/12/2004 | WO2004012749A1 An analgesic agent for newborn or fetal subjects |
| 02/12/2004 | WO2004012741A1 Sustained release formulations comprising lamotrigine |
| 02/12/2004 | WO2004012730A1 Improved transdermal delivery system for the administration of rotigotine |
| 02/12/2004 | WO2004012722A2 Bicifadine formulation |
| 02/12/2004 | WO2004012719A1 Improved transdermal delivery system |
| 02/12/2004 | WO2004012671A2 Substituted furo [2,3-b] pyridine derivatives |
| 02/12/2004 | WO2004012651A2 Composition for heart disease, method to prepare same and uses thereof |
| 02/12/2004 | WO2003103604A3 Gamma lactams as prostaglandin agonists and use thereof |
| 02/12/2004 | WO2003095437A8 Aralkyl formyl-alkyl piperazine derivatives and their uses as cerebral nerve protective agent |
| 02/12/2004 | WO2003091259A8 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/12/2004 | WO2003089456A3 Peptide inhibitors of protein kinase c |
| 02/12/2004 | WO2003086417B1 Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system |
| 02/12/2004 | WO2003082329A3 Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
| 02/12/2004 | WO2003070968A3 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/12/2004 | WO2003070236A3 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/12/2004 | WO2003070171A9 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells |
| 02/12/2004 | WO2003065994A3 Schwann cell and phosphodiesterase inhibitors based therapy |
| 02/12/2004 | WO2003060142A3 Compositions and methods for controlled release |
| 02/12/2004 | WO2003059264A3 Methods for the induction of professional and cytokine-producing regulatory cells |
| 02/12/2004 | WO2003050301A3 Susceptibility locus for schizophrenia |
| 02/12/2004 | WO2003049702A3 Vanilloid receptor ligands and their use in treatments |
| 02/12/2004 | WO2003044524A3 Methods and means for influencing intracellular communication and intracellular organelle transport |
| 02/12/2004 | WO2003037916A3 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/12/2004 | WO2003024976A3 Tricyclic indole derivatives as 5-ht ligands |
| 02/12/2004 | WO2003023056A3 Specific markers for multiple sclerosis |
| 02/12/2004 | WO2003020700A3 SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF |
| 02/12/2004 | WO2003015710A3 Combined drug and csf removal therapies and systems |
| 02/12/2004 | WO2003013424A3 Use of r-nsaid compounds for anti-hiv treatment |
| 02/12/2004 | WO2003010159A8 Piperidine derivatives as nmda receptor antagonists |
| 02/12/2004 | WO2003008365A3 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 02/12/2004 | WO2002100344A3 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| 02/12/2004 | WO2002100330A3 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES |
| 02/12/2004 | WO2002074346A3 Targeting chemical compounds to cells |
| 02/12/2004 | WO2002068461A3 Heterocarpine, a human ghrh-binding protein |
| 02/12/2004 | WO2002066647A3 Type 2 ctokine receptor and nucleic acids encoding same |
| 02/12/2004 | WO2002057454A3 Receptors and membrane-associated proteins |
| 02/12/2004 | WO2002053580A3 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |